Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 888271

Tumor necrosis factor antagonists in the treatment of pyoderma gangrenosum, acne and suppurative hidradenitis (PASH) syndrome


Saint-Georges, Valentina; Peternel, Sandra; Kaštelan, Marija; Brajac, Ines
Tumor necrosis factor antagonists in the treatment of pyoderma gangrenosum, acne and suppurative hidradenitis (PASH) syndrome // Acta dermatovenerologica Croatica, 26 (2018), 2; 173-178 (međunarodna recenzija, članak, stručni)


CROSBI ID: 888271 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Tumor necrosis factor antagonists in the treatment of pyoderma gangrenosum, acne and suppurative hidradenitis (PASH) syndrome

Autori
Saint-Georges, Valentina ; Peternel, Sandra ; Kaštelan, Marija ; Brajac, Ines

Izvornik
Acta dermatovenerologica Croatica (1330-027X) 26 (2018), 2; 173-178

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, stručni

Ključne riječi
acne ; adalimumab ; etanercept ; infliximab ; pyoderma gangrenosum ; suppurative hidradenitis

Sažetak
The clinical triad of pyoderma gangrenosum (PG), acne and suppurative hidradenitis (HS) has been described under the acronym PASH syndrome and is considered to represent a distinct entity in the group of autoinflammatory diseases. It is a fairly new, only recently recognized disorder with a limited number of reported cases and without defined treatment recommendations. We aimed to summarize currently available data on the use of tumor necrosis factor (TNF) antagonists in the management of PASH syndrome and report on our own experience with the use of adalimumab in a patient presenting with this specific constellation of clinical signs and symptoms. Among the 11 cases identified in the literature, infliximab and adalimumab were the most commonly used agents, both exhibiting favorable effects in the majority of, but not all, patients. This was particularly evident in terms of relatively rapid remission of PG whereas HS lesions seemed to be more resistant to treatment. In our patient, adalimumab monotherapy resulted in a remarkable and sustained remission, although significant improvement of HS lesions was observed only from week 16 of therapy onwards. In summary, TNF antagonists are a promising treatment for PASH ; however, conclusions regarding the choice of a specific agent, optimal dosing or use in combination with other treatment modalities cannot yet be drawn.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Ustanove:
Medicinski fakultet, Rijeka,
Klinički bolnički centar Rijeka,
Sveučilište u Rijeci

Profili:

Avatar Url Ines Brajac (autor)

Avatar Url Marija Kaštelan (autor)

Avatar Url Sandra Peternel (autor)

Citiraj ovu publikaciju

Saint-Georges, Valentina; Peternel, Sandra; Kaštelan, Marija; Brajac, Ines
Tumor necrosis factor antagonists in the treatment of pyoderma gangrenosum, acne and suppurative hidradenitis (PASH) syndrome // Acta dermatovenerologica Croatica, 26 (2018), 2; 173-178 (međunarodna recenzija, članak, stručni)
Saint-Georges, V., Peternel, S., Kaštelan, M. & Brajac, I. (2018) Tumor necrosis factor antagonists in the treatment of pyoderma gangrenosum, acne and suppurative hidradenitis (PASH) syndrome. Acta dermatovenerologica Croatica, 26 (2), 173-178.
@article{article, year = {2018}, pages = {173-178}, keywords = {acne, adalimumab, etanercept, infliximab, pyoderma gangrenosum, suppurative hidradenitis}, journal = {Acta dermatovenerologica Croatica}, volume = {26}, number = {2}, issn = {1330-027X}, title = {Tumor necrosis factor antagonists in the treatment of pyoderma gangrenosum, acne and suppurative hidradenitis (PASH) syndrome}, keyword = {acne, adalimumab, etanercept, infliximab, pyoderma gangrenosum, suppurative hidradenitis} }
@article{article, year = {2018}, pages = {173-178}, keywords = {acne, adalimumab, etanercept, infliximab, pyoderma gangrenosum, suppurative hidradenitis}, journal = {Acta dermatovenerologica Croatica}, volume = {26}, number = {2}, issn = {1330-027X}, title = {Tumor necrosis factor antagonists in the treatment of pyoderma gangrenosum, acne and suppurative hidradenitis (PASH) syndrome}, keyword = {acne, adalimumab, etanercept, infliximab, pyoderma gangrenosum, suppurative hidradenitis} }

Časopis indeksira:


  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE





Contrast
Increase Font
Decrease Font
Dyslexic Font